Description
Hydroxypyruvic acid lithium hydrate (β-Hydroxypyruvic acid lithium hydrate) is an intermediate in the metabolism of glycine, serine and threonine. Hydroxypyruvic acid lithium hydrate is a substrate for serine-pyruvate aminotransferase and glyoxylate reductase/hydroxypyruvate reductase. Hydroxypyruvic acid lithium hydrate is involved in the metabolic disorder which is the dimethylglycine dehydrogenase deficiency pathway.
Product information
CAS Number: 209728-15-4
Molecular Weight: 128.01
Formula: C3H5LiO5
Chemical Name: (hydrogeniooxy)hydrogen; lithio 3-hydroxy-2-oxopropanoate
Smiles: O.[Li]OC(=O)C(=O)CO
InChiKey: YHTVWBANKNBEKJ-UHFFFAOYSA-M
InChi: InChI=1S/C3H4O4.Li.H2O/c4-1-2(5)3(6)7;;/h4H,1H2,(H,6,7);;1H2/q;+1;/p-1
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In Vivo:
Hydroxypyruvic acid (lithium hydrate) (intravenous injection; 100 mg/ml; slowly over 10 min) increases the 5-h urinary oxalate and glycolate excretion to 0.68% (6.56 μmol) and 0.53% (5.10 μmol) in control rats, in addition, it increases to 2.43% (23.36 μmol) and 0.79% (7.59 μmol) of the dose in the vitamin-B6-deficient rats.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.